Skip to main content

Trexall Dosage

Medically reviewed by Drugs.com. Last updated on Apr 30, 2021.

Generic name: METHOTREXATE SODIUM 5mg
Dosage form: tablet, film coated

Important Dosage and Safety Information

Verify pregnancy status in females of reproductive potential before starting TREXALL [see Contraindications (4), Warnings and Precautions (5.1)].

Instruct patients and caregivers to take the recommended dosage as directed, because medication errors have led to deaths [see Warnings and Precautions (5.9)].

When switching the dosing regimen from oral administration to intravenous, intramuscular, or subcutaneous administration, an alternative dosing regimen may be necessary.

Do not administer to patients who are unable to swallow a tablet.

TREXALL is a cytotoxic drug. Follow applicable special handling and disposal procedures.1

Recommended Dosage for Neoplastic Diseases

Acute Lymphoblastic Leukemia

The recommended starting dosage of TREXALL is 20 mg/m2 orally once weekly, as part of a combination chemotherapy maintenance regimen. After initiating TREXALL, periodically monitor absolute neutrophil count (ANC) and platelet count and adjust the dose to maintain ANC at a desirable level and for excessive myelosuppression.

Mycosis Fungoides

The recommended dosage of TREXALL is 25 mg to 75 mg orally once weekly when administered as a single agent or 10 mg/m2 orally twice weekly as part of a combination chemotherapy regimen.

Relapsed or Refractory Non-Hodgkin Lymphomas

The recommended dosage of methotrexate is 2.5 mg orally 2 to 4 times per week (maximum 10 mg per week) as part of a metronomic combination chemotherapy regimen.

Recommended Dosage for Rheumatoid Arthritis

The recommended starting dosage of TREXALL is 7.5 mg orally once weekly with escalation to achieve optimal response. Dosages of more than 20 mg once weekly result in an increased risk of serious adverse reactions, including myelosuppression. When responses are observed, the majority occurred between 3 and 6 weeks from initiation of treatment; however, responses have occurred up to 12 weeks after treatment initiation.

Administer folic acid or folinic acid to reduce the risk of TREXALL adverse reactions [see Warnings and Precautions (5.10)].

Recommended Dosage for Polyarticular Juvenile Idiopathic Arthritis

The recommended starting dosage of TREXALL is 10 mg/m2 orally once weekly with escalation to achieve optimal response. Dosages of more than 30 mg/m2 once weekly result in an increased risk of serious adverse reactions, including myelosuppression. When responses are observed, the majority occurred between 3 and 6 weeks from initiation of treatment; however, responses have occurred up to 12 weeks after treatment initiation.

Administer folic acid or folinic acid to reduce the risk of TREXALL adverse reactions [see Warnings and Precautions (5.10)].

Recommended Dosage for Psoriasis

The recommended dosage of TREXALL is 10 mg to 25 mg orally once weekly until an adequate response is achieved. Adjust the dose gradually to achieve optimal clinical response; do not exceed a dose of 30 mg per week. Once optimal clinical response has been achieved, reduce the dosage to the lowest possible dosing regimen.

Administer folic acid or folinic acid supplementation to reduce the risk of TREXALL adverse reactions [see Warnings and Precautions (5.10)].

Dosage Modifications for Adverse Reactions

Discontinue TREXALL for:

  • Anaphylaxis or other severe hypersensitivity reactions [see Warnings and Precautions (5.2)]
  • Lymphoproliferative disease [see Warnings and Precautions (5.13)]

Withhold, dose reduce or discontinue TREXALL as appropriate for:

  • Myelosuppression [see Warnings and Precautions (5.3)]

Withhold or discontinue TREXALL as appropriate for:

  • Severe gastrointestinal toxicity [see Warnings and Precautions (5.4)]
  • Hepatotoxicity [see Warnings and Precautions (5.5)]
  • Pulmonary toxicity [see Warnings and Precautions (5.6)]
  • Severe dermatologic reactions [see Warnings and Precautions (5.7)]
  • Severe renal toxicity [see Warnings and Precautions (5.8)]
  • Serious infections [see Warnings and Precautions (5.11)]
  • Neurotoxicity [see Warnings and Precautions (5.12)]

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.